Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis.

@article{Fabris2010StudyOT,
  title={Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis.},
  author={Martina Fabris and Luca Quartuccio and Stefania Lombardi and Maurizio Benucci and Mariangela Manfredi and Marta Saracco and Fabiola Atzeni and Pia Morassi and Marco Amedeo Cimmino and Elena Pontarini and Cinzia Fabro and Raffaele A Pellerito and Piercarlo Sarzi-Puttini and Maurizio Cutolo and Antonio Carletto and Lisa Maria Bambara and Fabio Fischetti and Francesco Curcio and Elio Tonutti and Salvatore de Vita},
  journal={Reumatismo},
  year={2010},
  volume={62 4},
  pages={253-8}
}
OBJECTIVE Identification of genetic biomarkers of response to biologics in rheumatoid arthritis (RA) is a relevant issue. The -174G>C interleukin-6 (IL-6) promoter polymorphism was investigated in RA patients treated with rituximab (RTX), being IL-6 a key cytokine for B cell survival and proliferation, thus possibly implicated in rituximab efficacy. METHODS The study was conducted in a real-life retrospective cohort of 142 unselected RA patients (120F/22M) treated with RTX and referred to 7… CONTINUE READING
5 Citations
29 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Rheumatoid factor predicts response to rituximab in a European registry-based cohort: 6-month results from the collaborative European registries for rituximab in rheumatoid arthritis (CERERRA)

  • RF van Vollenhoven, K Chatzidionysiou, C. Gabay
  • Ann Rheum Dis 2009;
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…